A new Alzheimer’s drug is expected to be approved by the Food and Drug Administration (FDA). However, the medication works best mostly for those in the earliest stages of Alzheimer’s.
Deaths among older adults with dementia fell starkly in nursing homes and long-term care centers after COVID-19 vaccinations became available, but remained high for those living at home.